P2, N=126, Recruiting, Maastricht University Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
7 months ago
Trial completion date • Trial primary completion date • Metastases
Furthermore, intravenous administration of L19-mIL12 or L19-mTNF cured a proportion of tumor-bearing mice, whereas L19-IL2 did not. Systemic administration of the fully human L19-TNF fusion protein to patients with glioblastoma (NCT03779230) was safe, decreased regional blood perfusion within the tumor, and was associated with increasing tumor necrosis and an increase in tumor-infiltrating CD4 and CD8 T cells. The extensive preclinical characterization and subsequent clinical translation provide a robust basis for future studies with immunocytokines to treat malignant brain tumors.
P2, N=126, Recruiting, Maastricht University | Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
over 4 years ago
Clinical • Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
The data obtained with the comprehensive preclinical characterization and subsequent clinical translation form the basis for future studies with immunocytokines as novel treatment option for patients with malignant brain tumors. Research Funding: Philogen, Swiss National Sience Foundation
over 4 years ago
IO biomarker
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)